

TRACE EYE-D, LLC

SWGDRUG Alignment and Intended-Use Statements

F1 Fentanyl | M-39 Methamphetamine | W-42 Cannabinoid Detection Wipes

Important terminology: These are SWGDRUG alignment and intended-use statements. SWGDRUG does not certify or approve individual commercial presumptive field tests.

These statements are intended for inclusion in agency, laboratory, procurement, or compliance-review packets. They describe how each Trace Eye-D presumptive wipe is positioned relative to the analytical framework in SWGDRUG Recommendations Version 8.2. They do not represent SWGDRUG certification, endorsement, or approval of Trace Eye-D products.

Reference source: Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG), Recommendations Version 8.2, approved June 27, 2024, available from [swgdrug.org](https://www.swgdrug.org).

W-42 - Cannabinoid Presumptive Detection Wipe

Product	W-42 Cannabinoid Presumptive Detection Wipe
Manufacturer	Trace Eye-D, LLC
Document Type	SWGDRUG Alignment and Intended-Use Statement
Reference	SWGDRUG Recommendations Version 8.2, Parts III B and IV B

Trace Eye-D W-42 is a qualitative colorimetric presumptive screening test intended to indicate the presence of cannabinoids through a characteristic visible reaction.

Consistent with SWGDRUG Recommendations Version 8.2, W-42 functions as a Category C color test, providing general or class-level analytical information. Category C results may support an analytical scheme but do not independently provide the structural information necessary for definitive identification of a specific controlled substance.

W-42 is therefore intended to provide a presumptive indication of cannabinoid-containing material. It is not intended to quantify delta-9-THC concentration, establish statutory THC content, or independently differentiate marijuana from legally defined hemp. Where such a distinction is legally or evidentially necessary, an appropriately validated quantitative and/or confirmatory analytical method must be employed.

SWGDRUG emphasizes that individual qualitative methods have limitations and that reliable drug identification depends upon an appropriate combination of methods used by competent analysts within a quality-controlled analytical scheme.

Consistent with SWGDRUG validation principles, performance evaluation for W-42 should address selectivity and potential interferents, precision, operating range or detection limit, sample-matrix effects, and other characteristics relevant to the intended application.

Limitation: A positive W-42 reaction is a presumptive indication of cannabinoids within the validated scope of the test. It does not independently establish cannabinoid identity, delta-9-THC concentration, or the legal classification of the tested material.

Common Regulatory and Standards Notice

SWGDRUG does not certify, approve, or endorse individual commercial presumptive test products. This statement describes the intended use and classification of this product relative to the analytical framework contained in SWGDRUG Recommendations Version 8.2. Compliance with SWGDRUG laboratory recommendations ultimately depends upon the analytical scheme, validation or verification, quality system, reporting practices, and jurisdictional requirements of the laboratory or agency using the product.

Reference

Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG). SWGDRUG Recommendations, Version 8.2, approved June 27, 2024. Sections referenced: Part III B, Methods of Analysis and Analytical Scheme for Identification of Drugs or Chemicals; and Part IV B, Validation of Analytical Methods. Source: <https://swgdrug.org/>